Effects of smoked and oral THC on pain and intoxication based on age
Sex- and AGE-dependent Effects of Smoked and Oral Delta-9-THC
This study is testing how different ages affect the pain relief and intoxication from smoked and oral THC, to see if it works differently for younger and older adults.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 103 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05865470 on ClinicalTrials.gov |
What this trial studies
This outpatient study aims to evaluate how age influences the effects of smoked and oral Delta-9-THC on pain relief, abuse potential, intoxication, and impairment. It is a placebo-controlled trial that will compare the dose-dependent responses of participants aged 18 to 65 years, focusing on emerging adults, middle-aged adults, and late middle-aged adults. The study will also consider sex differences in these effects, providing a comprehensive understanding of THC's impact across different age groups.
Who should consider this trial
Good fit: Ideal candidates are males or non-pregnant females aged 18-65 who have used cannabis regularly and do not seek treatment for cannabis use.
Not a fit: Patients with significant substance use disorders or severe psychiatric illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into age-specific responses to THC, potentially guiding safer and more effective pain management strategies.
How similar studies have performed: Previous studies have explored the effects of cannabinoids, but this specific focus on age-dependent responses is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year) * Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening * Not currently seeking treatment for their cannabis use * No reported clinically significant adverse effects with cannabis use * Have a Body Mass Index from 18.5 - 34kg/m2 * Able to perform all study procedures * FEMALES: Currently practicing an effective form of birth control if pre-menopausal Exclusion Criteria: * Meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder * Report using other illicit drugs in the prior 4 weeks * Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * Current predominant licit use of medical cannabis * Current use of prescription or regular use of over the counter medications (with the exception of hormonal contraceptives and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin) * If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures * Current pain * Pregnancy is exclusionary due to the possible effects of the study medication on fetal development * History of an allergic reaction or adverse reaction to cannabis is exclusionary. * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary. * Intolerance to lactose and sesame (ingredients in the oral THC preparation) * Insensitivity to the Cold Pressor Test
Where this trial is running
Los Angeles, California
- UCLA Center for Cannabis and Cannabinoids — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Ziva Cooper, PhD — University of California, Los Angeles
- Study coordinator: Ziva D Cooper, PhD
- Email: zcooper@mednet.ucla.edu
- Phone: 310-983-3417
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.